Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 09 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Beijing 205 Taiyuan 6 Shenzhen 6 Anyang 5 Langfang 4
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Peking Union Medical College Hospital271 Beijing Tiantan Hospital219 Cancer Institute and Hospital, Chinese Academy of Medical Sciences205 AstraZeneca191 Peking University People's Hospital166 Clear sponsor filter
Site location
Beijing205 Taiyuan6 Shenzhen6 Anyang5 Langfang4
All 32 locations
Target enrolment
to

Trials with a site in Beijing

205 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1
27
Beijing
2026-11-01
Not yet open
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
87
Beijing
2026-11-01
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
73
Beijing
2026-10-08
Not yet open
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1
24
Beijing
2026-10-01
Not yet open
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
160
Taiyuan, Beijing, Shenzhen
2026-09
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
500
Beijing
2026-08-23
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1
21
Beijing
2026-08-12
Recruiting
Establishment of a Multi-omics Prediction Model for Early Triple-negative Breast Cancer Based on UPGRADE-TNBC Study
NCT07773818Triple -Negative Breast Cancertriple, Meta-Learning, Predictive Models, Multimodal
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
32
Beijing
2026-08-06
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
82
Beijing
2026-07-23
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1
12
Beijing
2026-07-06
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
46
Beijing
2026-07-03
Not yet open
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Early Phase 1
144
Beijing
2026-07-01
Active, closed
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
140
Beijing
2026-07-01
Not yet open
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
274
Beijing
2026-07-01
Not yet open
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1
91
Beijing
2026-07-01
Not yet open
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
1,200
Beijing
2026-07-01
Not yet open
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
300
Beijing, Shenzhen, Taiyuan
2026-07-01
Recruiting
Chemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric Cancer
NCT07689851Gastric Cancer (GC), Gastroesophageal Junction Adenocarcinoma
DrugRetlirafusp alfa
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
60
Shenzhen, Taiyuan, Beijing
2026-07-01
Not yet open
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
29
Beijing
2026-06-30
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
92
Beijing
2026-06-16
Not yet open
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
649
Beijing
2026-06-15
Active, closed
Induction Chemoimmunotherapy Followed by Deescalated Definitive Radiotherapy in Head and Neck Cancer
NCT07791602Head and Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck Cancer, HNSCC
DrugCamrelizumab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
180
Beijing, Harbin, Shenyang, Taiyuan, Tianjin
2026-06-12
Not yet open
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Early Phase 1
7
Beijing
2026-05-31
Not yet open
Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI
NCT07551414NSCLC (Non-small Cell Lung Carcinoma), Leptomeningeal Metastasis, EGFR-TKI Sensitizing Mutation, Zorifertinib
DrugZorifertinib
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
38
Beijing
2026-05-30
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
500
Hefei, Beijing, Fuzhou, Xiamen, Shijiazhuang, Zhengzhou, Shiyan, Wuhan
2026-05-28
Active, closed
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
45
Beijing
2026-05-14
Not yet open
PTC-Guided Atorvastatin Plus Axitinib and Toripalimab in Advanced RCC
NCT07630363Advanced Renal Cell Carcinoma (RCC), PTC, Atorvastatin, Targeted Therapy Combined With Immunotherapy
DrugsAxitinib·Atorvastatin·Toripalimab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1/2
40
Beijing
2026-05-14
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
300
Beijing
2026-05-02
Not yet open
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3
204
Beijing
2026-05-01
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3
651
Beijing
2026-05-01
Recruiting
Characterization of Multi-Omics Landscapes and AI Pathological Prediction Model for Long-Term Survival in NSCLC Immunotherapy
NCT07668037Non-Small Cell Carcinoma of Lung, Immunotherapy, Advanced Non-Small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
600
Beijing
2026-05-01
Not yet open
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1
10
Beijing
2026-04-30
Not yet open
Omitting Nasogastric Tube Decompression in Minimally Invasive Pancreaticoduodenectomy
NCT07370116Pancreaticoduodenectomy, Nasogastric Tube Decompression, Minimally Invasive Surgical Procedures
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
200
Beijing
2026-04-01
Not yet open
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
60
Beijing
2026-04-01
Recruiting
Hypofractionated vs Conventional RT After Prosthetic Breast Reconstruction
NCT07084519Breast Cancer, Breast Reconstruction, Radiation Oncology
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3
506
Beijing
2026-03-27
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3
350
Beijing, Shenzhen
2026-03-17
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1
55
Beijing
2026-03-03
By invitation
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
4,000
Beijing
2026-03-02
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
250
Beijing
2026-03-01
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
184
Beijing
2026-03-01
Recruiting
A Retrospective Real-World Study Based on RATIONALE-307
NCT07478809NSCLC (Advanced Non-small Cell Lung Cancer)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
109
Beijing
2026-02-28
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1
9
Beijing
2026-02-20
Not yet open
Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer
NCT07317778Breast Cancer Early Stage Breast Cancer (Stage 1-3), HR Positive/HER2 Low Breast Cancer
DrugsTrastuzumab Rezetecan·Adebrelimab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
249
Beijing
2026-02-15
Not yet open
Preoperative Hypofractionated RT + Immunotherapy & Surgery for Retroperitoneal Sarcoma (FUSION-02)
NCT07396116Soft Tissue Sarcoma (STS), Retroperitoneal Sarcoma, Immunotherapy, Radiotherapy Side Effect
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
28
Beijing
2026-02-12
Not yet open
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
78
Beijing
2026-02-10
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
30
Beijing
2026-02-01
Not yet open
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3
3,142
Beijing
2026-02-01
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
157
Beijing
2026-02
Not yet open
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Early Phase 1
20
Beijing
2026-01-31
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
46
Beijing
2026-01-16
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Early Phase 1
36
Beijing
2026-01-10
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1/2
29
Beijing
2026-01-05
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
900
Beijing
2026-01-01
Active, closed
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
40
Beijing
2026-01-01
Active, closed
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
300
Beijing
2026-01-01
Active, closed
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
60
Beijing
2026-01-01
By invitation
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
354
Beijing
2026-01-01
Not yet open
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
292
Beijing
2025-12-31
Active, closed
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
9
Beijing
2025-12-31
Recruiting
Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia in Pediatric Cancer Patients
NCT07043894Solid Tumors, Hematological Tumor, Children, Adolescent
DrugIpilimumab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
50
Beijing
2025-12-25
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1/2
198
Beijing
2025-12-25
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Early Phase 1
15
Beijing
2025-12-18
By invitation
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Early Phase 1
19
Beijing
2025-12-18
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Early Phase 1
36
Beijing
2025-11-27
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Early Phase 1
50
Beijing
2025-11-21
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
30
Beijing, Zhengzhou, Shenyang, Taiyuan
2025-11-12
Recruiting
Iparomlimab/Tuvonralimab Injection Plus CCRT in LACC
NCT07232654LOCALLY ADVANCED CERVICAL CANCERS
DrugsLenvatinib·Cisplatin
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
30
Beijing
2025-11-11
Recruiting
CONNEctome-guided Navigation for Eloquent-area Tumor Surgery Trial
NCT07657403Brain Neoplasms, Eloquent Area Brain Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
200
Beijing
2025-11-01
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
20
Beijing, Chongqing
2025-10-31
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
108
Beijing
2025-10-28
Active, closed
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
300
Beijing
2025-10-01
Active, closed
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
65
Beijing
2025-10-01
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
40
Beijing
2025-09-18
Recruiting
A Phase I Study of CREPT-618 in Locally Advanced HCC
NCT07364357Hepatocellular Carcinoma (HCC)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1
13
Beijing
2025-09-15
Active, closed
Predictive Biomarkers for PD-1 Inhibitor Response in Squamous Cell Carcinoma
NCT07147361Esophageal Squamous Cell Carcinoma (ESCC), Cervical Squamous Cell Carcinoma, Lung Squamous Cell Carcinoma, Head and Neck Squamous Carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
800
Beijing
2025-09-12
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Early Phase 1
10
Beijing
2025-09-01
Not yet open
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
180
Beijing
2025-09
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3
134
Beijing
2025-08-29
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1
16
Beijing
2025-08-28
Recruiting
CTR-FAPI-guided Precision Surgery for Newly Diagnosed MTC
NCT07383246Medullary Thyroid Carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3
150
Beijing
2025-08-25
Active, closed
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
40
Beijing
2025-08-01
Not yet open
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
90
Beijing
2025-08-01
Recruiting
Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC
NCT06897046Non-small Cell Lung Cancer (NSCLC), II-IIIB
DrugsLenvatinib·Carboplatin
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
90
Beijing
2025-07-30
By invitation
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2/3
32
Beijing
2025-07-21
Recruiting
Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC
NCT07186621Hepatocellular Carcinoma (HCC), Radiotherapy, Adjuvant, Immune Checkpoint Inhibitor, TACE
DrugSintilimab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3
286
Beijing
2025-07-10
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
48
Beijing
2025-06-25
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
132
Beijing
2025-06-12
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
224
Beijing
2025-06-11
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Early Phase 1
136
Beijing
2025-06-01
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
228
Beijing, Shenzhen
2025-06-01
Recruiting
A Prospective Phase II Study of Postoperative Concurrent Chemoradiotherapy in Patients With Intrahepatic Cholangiocarcinoma
NCT07063888Intrahepatic Cholangiocarcinoma (Icc), Adjuvant Chemoradiotherapy, Narrow Margin, Lymph Node Involvement
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
66
Beijing
2025-05-16
Recruiting
Using 4D Urinary Proteomics to Predict and Evaluate Treatment Response in Colorectal Cancer
NCT06904677Colorectal Cancer (CRC), Neoadjuvant Therapy, Proteomics
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
400
Beijing
2025-05-01
Recruiting
Efficacy of Neoadjuvant Immunotherapy in Patients With Lung Cancer
NCT07166003Lung Cancer, Non-Small Cell, Immunotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
500
Beijing
2025-04-20
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
50
Beijing
2025-04-12
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
40
Beijing
2025-04-12
Recruiting
Prospective Study of Cadonilimab With Lenvatinib in Renal Cell Carcinoma
NCT07909265Renal Cell Carcinoma (Kidney Cancer), Clear Cell Renal Cell Carcinoma
DrugCadonilimab lenvatinib
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
54
Beijing
2025-04-01
Not yet open
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
600
Beijing
2025-04-01
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
170
Beijing
2025-03-31
By invitation
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
250
Beijing
2025-03-15
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
102
Beijing
2025-03-01
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
100
Beijing
2025-03-01
Not yet open
Familial Breast Cancer in China
NCT06833216Breast Carcinoma, Genetic Variation
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
500
Beijing
2025-02-28
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
61
Beijing
2025-02-28
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Early Phase 1
83
Beijing
2025-02-24
Not yet open
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
30
Beijing
2025-02-15
Not yet open
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
9
Beijing
2025-02-15
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
128
Beijing
2025-01-25
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
49
Beijing
2025-01-24
By invitation
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
300
Beijing
2025-01-19
Recruiting
Sintilimab Combined With Chemotherapy as Adjuvant Treatment for Phase III GC and GEJ
NCT06761846Gastric Adenocarcinoma, Esophagogastric Junction Adenocarcinoma
DrugSintilimab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
70
Beijing
2025-01-17
By invitation
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
3,000
Beijing
2025-01-01
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
40
Beijing
2025-01-01
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
40
Beijing
2025-01-01
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
40
Beijing
2025-01-01
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
166
Beijing
2025-01-01
Recruiting
Adaptive Radiotherapy for Genitourinary Cancers
NCT07324798Prostate Cancer (Post Prostatectomy), Bladder Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
60
Beijing
2024-12-01
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
15
Beijing
2024-11-25
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3
3,142
Beijing
2024-10-10
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
150
Beijing
2024-09-24
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
150
Beijing
2024-09-10
Recruiting
First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma
NCT05188859Mesothelioma, Malignant, Mesothelioma, Malignant Pleural, Mesothelioma Malignant Advanced
DrugsAnlotinib·Sintilimab·Pemetrexed·Cisplatin
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
29
Taiyuan, Beijing
2024-09-01
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
30
Beijing
2024-08-30
By invitation
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
536
Beijing
2024-08-22
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
30
Beijing
2024-08-15
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
94
Beijing
2024-07-11
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1/2
100
Beijing
2024-05-24
Active, closed
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
40
Beijing
2024-05-24
Recruiting
Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer
NCT06413992Endometrial Carcinoma, TP53 Mutation, Recurrent or Metastatic
DrugsFluzoparib·Camrelizumab·Paclitaxel·Carboplatin
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
117
Beijing
2024-05-10
By invitation
Intensive Adjuvant Therapy for TNBC with BRCA Gene Mutation
NCT06405295Breast Carcinoma, BRCA Mutation, Adjuvant Drug Therapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
600
Beijing
2024-05-06
By invitation
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
600
Beijing
2024-05-06
Recruiting
Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer
NCT06421376Esophageal Cancer, Immunotherapy, Induction Therapy, Chemoradiotherapy
DrugCardonilizumab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
60
Anyang, Xinxiang, Beijing
2024-05-01
Active, closed
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
240
Beijing
2024-05-01
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
36
Beijing
2024-05-01
Recruiting
Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis
NCT06389422Hepatocellular Carcinoma, Radiotherapy, Pembrolizumab, Tumor Thrombosis
DrugPembrolizumab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
30
Beijing
2024-05-01
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2/3
964
Beijing
2024-04-30
Recruiting
NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC
NCT06405490Nanoliposomal Irinotecan, Cadonilimab, Oxaliplatin, Capecitabine
DrugsNanoliposomal Irinotecan·Cadonilimab·Capecitabine·Oxaliplatin
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
30
Beijing
2024-04-17
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
60
Beijing
2024-04-15
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Early Phase 1
19
Beijing
2024-04-12
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
90
Beijing
2024-04-01
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
400
Beijing, Chongqing, Fuzhou, Anyang, Zhengzhou, Huai'an, Nanjing, Jinan
2024-03-30
Recruiting
Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma
NCT06342167Locally Advanced Esophageal Squamous Cell Carcinoma, Sintilimab, Radiotherapy, Concurrent Chemoradiotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
57
Beijing, Fujian, Handan, Anyang, Xinxiang, Yinchuan, Feixian, Jining
2024-03-14
By invitation
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
138
Beijing
2024-03-01
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
20,000
Beijing
2024-03-01
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
4,000
Beijing
2024-03-01
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
67
Beijing
2024-03-01
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3
436
Beijing
2024-02-04
Recruiting
Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM
NCT06543069Malignant Peritoneal Mesothelioma, Advanced
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
28
Beijing
2024-01-31
Not yet open
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 4
51
Beijing
2024-01-30
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
100
Beijing
2024-01-26
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1
60
Beijing
2024-01-24
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
44
Beijing
2024-01-23
Recruiting
Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer
NCT06197581Breast Cancer, Familial Male, Radiotherapy; Complications, Chemotherapeutic Toxicity, Immune Checkpoint Inhibitor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
148
Beijing
2024-01-12
Active, closed
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
57
Beijing
2024-01-09
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
300
Beijing
2024-01-01
By invitation
Hypofractionated Radiotherapy for HNSCC in Elderly Patients
NCT06768125Head and Neck Cancer Squamous Cell Carcinoma, ELDERLY PEOPLE, Hypofractionation
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
51
Beijing
2024-01-01
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
133
Beijing
2024-01-01
Not yet open
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
69
Beijing
2024-01
Recruiting
NV-001 in the Treatment of Advanced Solid Tumors
NCT06051760Malignant Neoplasm
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1
20
Beijing
2023-12-01
Recruiting
Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC
NCT06170710Head and Neck Squamous Cell Carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
173
Beijing
2023-12-01
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
1,384
Beijing, Shanghai, Chengdu
2023-12-01
Not yet open
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3
366
Beijing
2023-11-30
Active, closed
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
50
Beijing
2023-11-11
Recruiting
Personalized KSX01-TCRT in Patients With Advanced Solid Tumors
NCT06150365Refractory Solid Tumors, Relapsed Solid Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Early Phase 1
12
Beijing
2023-11-07
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
170
Beijing, Guangzhou, Jinan
2023-11-01
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
120
Beijing
2023-10-16
Recruiting
68Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTC
NCT06277180Medullary Thyroid Cancer, Prositron Emission Tomography, Fibroblast Activation Protein Inhibitor, Surgery
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
50
Beijing
2023-10-01
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1/2
40
Beijing
2023-09-15
Recruiting
SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC
NCT06457906Small-cell Lung Cancer, Brain Metastases, SRS, Stereotactic Radiotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3
340
Beijing
2023-09-01
Not yet open
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
181
Beijing
2023-09-01
Not yet open
Fluorescence Laparoscopic Navigation for Rectal Cancer and Sigmoid Colon Cancer
NCT05730595Colorectal Neoplasms, Fluorescence, Lymph Node Excision
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
550
Hefei, Beijing, Chengdu, Fuzhou, Guangzhou, Shijiazhuang, Haerbin, Nanjing
2023-09-01
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
102
Beijing
2023-07-20
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1/2
60
Beijing
2023-05-11
Recruiting
Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma
NCT06410651Esophageal Cancer, Nimotuzumab, Chemoradiotherapy, Chemotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
53
Beijing
2023-03-01
Recruiting
Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients
NCT06429839Esophageal Cancer, Nimotuzumab, Chemoradiotherapy, Chemotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
55
Beijing
2023-03-01
Active, closed
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
50
Beijing
2023-01-20
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
204
Beijing
2023-01-01
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2/3
400
Beijing
2022-12-20
Active, closed
Additional Consolidative Esophagectomy for the Patients With Oligometastatic Resectable ESCC
NCT05951127Esophageal Squamous Cell Carcinoma, Oligometastatic Disease
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
141
Beijing
2022-11-01
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
65
Beijing
2022-10-25
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
400
Beijing
2022-10-13
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
68
Beijing
2022-08-25
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
140
Beijing
2022-08-01
Recruiting
Right Versus Left Thoracic Surgical Approaches for Siewert II Gastroesophageal Junction Adenocarcinoma
NCT06644352Siewert Type II Adenocarcinoma of Esophagogastric Junction
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
236
Beijing
2022-07-01
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3
1,199
Beijing
2022-07-01
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
102
Beijing
2022-06-21
Not yet open
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
53
Beijing
2022-06
Recruiting
Super-Hypofractionated Partial Breast Irradiation
NCT06615466Breast Cancer, Radiotherapy Side Effect
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
50
Beijing
2022-04-22
Recruiting
Surgery or Chemoradiotherapy for Cervical Esophageal Cancer
NCT05327517Cervical Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
192
Beijing
2022-04-10
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
300
Beijing, Langfang
2022-03-24
Recruiting
Preoperative Ultra-hypofractionated Radiotherapy Followed by Surgery for Retroperitoneal Sarcoma (FUSION-01)
NCT05224934Soft Tissue Sarcoma, Retroperitoneal Sarcoma, Radiotherapy Side Effect, Ultra-hypofractionated Radiotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
50
Beijing
2022-01-01
Active, closed
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
43
Beijing
2021-05-12
Recruiting
MR-linac Guided Ultra-hypofractionated RT for Prostate Cancer (SMART-P01 and SMART-P02)
NCT05183074Prostate Cancer, Radiotherapy Side Effect, Magnetic Resonance-linac, Stereotactic Ablative RT
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
50
Beijing
2021-02-01
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
900
Beijing
2021-01-01
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
770
Beijing
2020-08-15
Active, closed
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3
2,400
Beijing
2020-05-08
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
30
Beijing
2020-05-01
Active, closed
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
10,000
Beijing
2020-01-01
Recruiting
Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers
NCT06255197Lung Cancer, Lung Adenocarcinoma, Lung Squamous Cell Carcinoma, Non Small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
60,000
Beijing
2019-11-04
Recruiting
Chemoradiotherapy in Unresectable Esophageal Cancer
NCT04278287Esophageal Cancer, Chemoradiotherapy, Albumin-bound Paxlitaxel, Unresectable Malignant Neoplasm
DrugsAlbumin-Bound Paclitaxel·Nab-paclitaxel·Cisplatin
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1/2
105
Anyang, Changsha, Nanjing, Beijing
2019-10-01
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
8,000
Beijing
2019-01-01
Active, closed
Accelerated Partial Breast Irradiation With IMRT in Early Breast Cancer
NCT03583580Breast Neoplasms, Neoplasm Recurrence, Local
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
537
Beijing
2018-07-19
Active, closed
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
500
Beijing
2018-01-23
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
300
Beijing
2016-10
Recruiting
Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer
NCT04821778Esophagus Cancer, Esophagogastric Junction Cancer, Chemoradiation, Targeted Therapy
DrugNimotuzumab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3
2,000
Anyang, Changsha, Nanjing, Beijing
2002-01-01
Recruiting
Neoadjuvant Treatment Modalities in Esophageal Cancer
NCT04821843Esophageal Cancer, Chemotherapy Effect, Chemoradiation, Surgery
DrugNimotuzumab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3
2,000
Beijing
2002-01-01
Rows per page Showing 1–205 of 205
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 November 2026. https://priyalifescience.com/clinical-trials-china/city/beijing

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 09 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 205 of those studies with a site in Beijing that also match the filters currently applied.

How many clinical trials are recruiting in Beijing?

135 of the 205 studies on this page are recruiting new participants as of the 09 Nov 2026, 03:17 UTC sync. A further 36 have not yet opened recruitment, 22 are active but closed to new participants, and 12 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Beijing), 205 studies
PhaseStudiesRecruitingShare
Phase 2855941.5%
Observational392119%
Not applicable291814.1%
Phase 316127.8%
Early Phase 11396.3%
Phase 11285.9%
Phase 1/2763.4%
Phase 2/3321.5%
Phase 4100.5%

Most active sponsors

Lead sponsors with the most studies (Beijing)
Lead sponsorStudiesRecruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences205135
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.